Cardioprotection thread, page-569

Apologies for the mess with posts here. Hopefully, this is a format that HotCopper can support so people can read without having to click and zoom on the image. It's quite funny HotCopper formatting can't handle the volume of evidence available supporting the role of FTO in cancer and chemoresistance.

Summary:
FTO is an influential protein in 25 different drug classes
- Inhibition or overexpression of FTO influences the activity of commercially available and experimental anti-cancer agents
- The inhibition of FTO resensitizes resistant cancer to the drug it was previously resistant to - this is akin to hitting a reset button

FTO is an influential protein in 71% of drug classes evaluated by Doan et al.
- Inhibition or overexpression of FTO influences the activity of commercially available cardiotoxic anti-cancer agents
- Bisantrene beautifully poised to address an enormous, unique unment need in cancer therapy globally

Preclinical evidence highlights the in-human efficacy of Bisantrene in combination with Ara-C (57% CR in Ara-C resistant pediatric AML patients) and Clofarabine and Fludarabine (40% ORR [5CR / 1PR] in heavily pretreated, refractory AML patients) with no clinical signs of cardiotoxicity
- FTO overexpression main driver in antimetabolite resistance in multiple cancer types
- FTO inhibition/knockdown resensitizes resistant cancer to the drug it was previously resistant to
- Bisantrene prevents cardiotoxicity of anthracyclines (Dox, Dauno, Epi) and proteasome inhibitors (carfilzomib, bortezimib)
- Clofarabine and Fludarabine present clinical signs of cardiotoxicity
- Ara-C is not frequently associated with cardiotoxicity

It's really up to investors to determine the likelihood of successful synergy between Bisantrene and Anthracyclines in the upcoming CPACS trial. For those who are well-read on Bisantrene, I suspect that you represent an extremely small percentage of the population that understand the m6A + cardioprotection opportunity. Only time will tell.



Reference list - RAC - Cardio + FTO DataREF.pdf